Key points are not available for this paper at this time.
Design
Editorial
Discusses the Global Polio Eradication Initiative's strategy regarding the cessation of live-attenuated oral poliovirus vaccines.
The Global Polio Eradication Initiative (GPEI), which launched in 1988 with a mandate to eradicate polio by 2000,1 has maintained its mission to stop and prevent the transmission of all three serotypes (1, 2, and 3) of wild poliovirus (WPV). Ultimately, ending all cases of poliomyelitis requires successful cessation of the use of all live-attenuated oral poliovirus vaccines (OPV) after certification of WPV eradication. Global transmission of serotype-2 WPV ended before 2000; in September, 2015, the world certified serotype-2 WPV eradication;2 and in late April and early May, 2016, the GPEI globally coordinated the cessation of all use of serotype -2-containing OPV (OPV2), except for in emergency uses to respond to serotype-2 outbreaks.
No takes yet. Share an insight, caveat, or question.
Kimberly M. Thompson (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: